File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1016/j.beha.2019.06.005
- Scopus: eid_2-s2.0-85067188447
- PMID: 31585625
- WOS: WOS:000494882700007
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: NK/T-cell lymphomas
Title | NK/T-cell lymphomas |
---|---|
Authors | |
Keywords | NK/T-cell lymphoma Nasal Non-nasal EBV PET/CT |
Issue Date | 2019 |
Publisher | Bailliere Tindall. The Journal's web site is located at http://www.elsevier.com/locate/issn/15216926 |
Citation | Best Practice & Research: Clinical Haematology, 2019, v. 32 n. 3, p. 253-261 How to Cite? |
Abstract | NK/T-cell lymphomas are extranodal EBV-related malignancies, mostly of NK-cell and occasionally of T-cell lineage. They are divided into nasal, non-nasal, and disseminated subtypes. Nasal NK/T-cell lymphomas involve the nose, nasopharynx and the upper aerodigestive tract. Non-nasal NK/T-cell lymphomas involve the skin, gastrointestinal tract, testis and other sites. Disseminated NK/T-cell lymphoma involves multiple organs, and may present with a leukemic phase. Initial evaluation requires positron emission tomography computed tomography (PET/CT) and quantification of circulating EBV DNA. Radiotherapy alone is inadequate with frequent relapses. Anthracycline-containing regimens are ineffective. Regimens incorporating asparaginase are currently the standard. For stage I/II disease, combined chemotherapy and radiotherapy is recommended. For stage III/IV disease, asparaginase-containing regimens are needed. Autologous hematopoietic stem cell transplantation (HSCT) is of limited efficacy, whereas allogeneic HSCT may be useful in patients with stage III/IV and relapsed diseases. Immunotherapy with antibodies against CD30, programmed cell death protein 1 and CD38 is promising. |
Persistent Identifier | http://hdl.handle.net/10722/289386 |
ISSN | 2023 Impact Factor: 2.2 2023 SCImago Journal Rankings: 0.864 |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Tse, E | - |
dc.contributor.author | Kwong, YL | - |
dc.date.accessioned | 2020-10-22T08:11:55Z | - |
dc.date.available | 2020-10-22T08:11:55Z | - |
dc.date.issued | 2019 | - |
dc.identifier.citation | Best Practice & Research: Clinical Haematology, 2019, v. 32 n. 3, p. 253-261 | - |
dc.identifier.issn | 1521-6926 | - |
dc.identifier.uri | http://hdl.handle.net/10722/289386 | - |
dc.description.abstract | NK/T-cell lymphomas are extranodal EBV-related malignancies, mostly of NK-cell and occasionally of T-cell lineage. They are divided into nasal, non-nasal, and disseminated subtypes. Nasal NK/T-cell lymphomas involve the nose, nasopharynx and the upper aerodigestive tract. Non-nasal NK/T-cell lymphomas involve the skin, gastrointestinal tract, testis and other sites. Disseminated NK/T-cell lymphoma involves multiple organs, and may present with a leukemic phase. Initial evaluation requires positron emission tomography computed tomography (PET/CT) and quantification of circulating EBV DNA. Radiotherapy alone is inadequate with frequent relapses. Anthracycline-containing regimens are ineffective. Regimens incorporating asparaginase are currently the standard. For stage I/II disease, combined chemotherapy and radiotherapy is recommended. For stage III/IV disease, asparaginase-containing regimens are needed. Autologous hematopoietic stem cell transplantation (HSCT) is of limited efficacy, whereas allogeneic HSCT may be useful in patients with stage III/IV and relapsed diseases. Immunotherapy with antibodies against CD30, programmed cell death protein 1 and CD38 is promising. | - |
dc.language | eng | - |
dc.publisher | Bailliere Tindall. The Journal's web site is located at http://www.elsevier.com/locate/issn/15216926 | - |
dc.relation.ispartof | Best Practice & Research: Clinical Haematology | - |
dc.subject | NK/T-cell lymphoma | - |
dc.subject | Nasal | - |
dc.subject | Non-nasal | - |
dc.subject | EBV | - |
dc.subject | PET/CT | - |
dc.title | NK/T-cell lymphomas | - |
dc.type | Article | - |
dc.identifier.email | Tse, E: ewctse@hku.hk | - |
dc.identifier.email | Kwong, YL: ylkwong@hkucc.hku.hk | - |
dc.identifier.authority | Tse, E=rp00471 | - |
dc.identifier.authority | Kwong, YL=rp00358 | - |
dc.description.nature | link_to_subscribed_fulltext | - |
dc.identifier.doi | 10.1016/j.beha.2019.06.005 | - |
dc.identifier.pmid | 31585625 | - |
dc.identifier.scopus | eid_2-s2.0-85067188447 | - |
dc.identifier.hkuros | 317069 | - |
dc.identifier.volume | 32 | - |
dc.identifier.issue | 3 | - |
dc.identifier.spage | 253 | - |
dc.identifier.epage | 261 | - |
dc.identifier.isi | WOS:000494882700007 | - |
dc.publisher.place | United Kingdom | - |
dc.identifier.issnl | 1521-6926 | - |